# References

### References & Information

#### 1  
A. C. Andersen. _The beagle as an experimental dog_. Iowa State University Press. University of Michigan. 616 pages. 1970.

#### 2
[N. Balakrishnan (Editor). _Methods and Applications of Statistics in Clinical Trials, Volume 2: Planning, Analysis, and Inferential Methods_. John Wiley and Sons. 2014.](https://www.wiley.com/en-us/Methods+and+Applications+of+Statistics+in+Clinical+Trials,+Volume+2%3A+Planning,+Analysis,+and+Inferential+Methods-p-9781118304761)

#### 3
[L. Baxter, H. Zhu, D. Mackensen, and R. Jain. _Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice_. Cancer Research. 54. 1517-28. 1994.](https://pubmed.ncbi.nlm.nih.gov/8137258)

#### 4
[L.Z. Benet. _Basic Principles and Its Use as a Tool in Drug Metabolism_. in: Drug Metabolism and Drug Toxicity. J.R. Mitchell. M.G. Horning. Raven Press. New York, USA. pp. 199. 1984.](https://doi.org/10.1002/em.2860070617)

#### 5
[L.M. Berezhkovskiy. _Volume of distribution at steady state for a linear pharmacokinetic system with peripheral elimination_. Journal of Pharmaceutical Sciences. 93(6). 1628-40. 2004.](https://pubmed.ncbi.nlm.nih.gov/15124219)

#### 6
[A. C. Hindmarsh, P. N. Brown, K. E. Grant, S. L. Lee, R. Serban, D. E. Shumaker, and C. S. Woodward. _SUNDIALS: Suite of Nonlinear and Differential/Algebraic Equation Solvers_. ACM Transactions on Mathematical Software, 31(3), pp. 363-396, 2005.](https://computing.llnl.gov/sites/default/files/toms_sundials.pdf)

#### 7
[P. Costa and J. M. Sousa Lobo. _Modeling and comparison of dissolution profiles_. Eur J Pharm Sci. 13(2). 123-33. 2001.](https://pubmed.ncbi.nlm.nih.gov/11297896)

#### 8
C. Crone and D.G. Levitt. _Capillary permeability to small solutes_. in Handbook of Physiology: The Cardiovascular System: Microcirculation. E.M. Renkin. C.C. Michel. American Physiological Society. Bethesda, MD, USA. pp. 411–466. 1984.

#### 9
[C. Dordas and P. H. Brown. _Permeability of Boric Acids across Lipid Bilayers and Factors Affecting it_. Journal of Membrane Biology. 175. 95-105. 2000.](https://pubmed.ncbi.nlm.nih.gov/10811971)

#### 10
[J.B. Dressman, K. Thelen, and E. Jantratid. _Towards Quantitative Prediction of Oral Drug Absorption_. Clinical Pharmacokinetics. 47(10). 655-67. 2008.](https://pubmed.ncbi.nlm.nih.gov/18783296)

#### 11
[A. N. Edginton, S. Willmann, B. Voith, and W. Schmitt. _A mechanistic approach to the scaling of clearance in children_. Clinical Pharmacokinetics. 45. 683-704. 2006.](https://pubmed.ncbi.nlm.nih.gov/16802850)

#### 12
[A. N. Edginton, W. Schmitt, and S. Willmann. _Application of physiology-based pharmacokinetic and pharmacodynamic modeling_ towards individualized propofol target controlled infusion. Advances in Therapy. 23. 143-158. 2006.](https://pubmed.ncbi.nlm.nih.gov/16644615/)

#### 13
[A. N. Edginton, W. Schmitt, and S. Willmann. _Development and evaluation of a generic physiologically based pharmacokinetic model for children_. Clinical Pharmacokinetics. 45. 1013-1034. 2006.](https://pubmed.ncbi.nlm.nih.gov/16984214)

#### 14
[A. N. Edginton, F.P. Theil, W. Schmitt, and S. Willmann. _Whole body physiologically-based pharmacokinetic models: their use in clinical drug development_. Expert Opinion on Drug Metabolism & Toxicology. 4(9). 1143-52. 2008.](https://pubmed.ncbi.nlm.nih.gov/18721109)

#### 15
[A.N. Edginton, G. Ahr, S. Willmann, and H. Stass. _Defining the Role of Macrophages in Local Moxifloxacin Tissue Concentrations using Biopsy Data and Whole-Body Physiologically Based Pharmacokinetic Modelling_. Clinical Pharmacokinetics. 48(3). 181-7. 2009.](https://pubmed.ncbi.nlm.nih.gov/19385711)

#### 16
[A. N. Edginton and G. Joshi. _Have physiologically-based pharmacokinetic models delivered?_. Expert Opin Drug Metab Toxicol. 929-34. 7(8). 2011.](https://pubmed.ncbi.nlm.nih.gov/21762039)

#### 17
[A. N. Edginton and S. Willmann. _Physiology-based simulations of a pathological condition : prediction of pharmacokinetics in patients with liver cirrhosis_. Clinical Pharmacokinetics. 47(11). 743-52. 2008.](https://pubmed.ncbi.nlm.nih.gov/18840029)

#### 18
[T. Eissing, L. Kuepfer, C. Becker, M. Block, K. Coboeken, T. Gaub, L. Goerlitz, J. Jaeger, R. Loosen, B. Ludewig, M. Meyer, C. Niederalt, M. Sevestre, H. U. Siegmund, J. Solodenko, K. Thelen, U. Telle, W. Weiss, T. Wendl, S. Willmann, and J. Lippert. _A computational systems biology software platform for multiscale modeling and simulation: integrating whole-body physiology, disease biology, and molecular reaction networks_. Front Physiol. 4. 2. 2011.](https://pubmed.ncbi.nlm.nih.gov/21483730)

#### 19
[T. Eissing, J. Lippert, and S. Willmann. _Pharmacogenomics of Codeine, Morphine, and Morphine-6-Glucuronide: Model-Based Analysis of the Influence of CYP2D6 Activity, UGT2B7 Activity, Renal Impairment, and CYP3A4 Inhibition_. Mol Diagn Ther. 43-53. 16(1). 2012.](https://pubmed.ncbi.nlm.nih.gov/22352453)

#### 20
[C.T. Ekstrom (Editor). _Introduction to Statistical Data Analysis for the Life Sciences, Second Edition_. CRC Press. 2014.](https://doi.org/10.1201/b17625)

#### 21
[B. I. Escher and R. P. Schwarzenbach. _Partitioning of Substituted Phenols in Liposome-Water, Biomembrane-Water, and Octanol-Water Systems_. Environmental Science and Technology. 30. 260-270. 1996.](https://doi.org/10.1021/es9503084)

#### 22
[P. Espie, D. Tytgat, M. L. Sargentini-Maier, I. Poggesi, and J. B. Watelet. _Physiologically based pharmacokinetics (PBPK)_. Drug Metab Rev. 41. 391-407. 2009.](https://pubmed.ncbi.nlm.nih.gov/19601719)

#### 23
[L. Fahrmeir, T. Kneib, and S. Lang. _Regression Modelle, Methoden und Anwendungen_. Springer Verlag. 2009.](https://www.springer.com/de/book/9783642018367)

#### 24
[F. Frezard and A. Garnier-Suillerot. _Permeability of Lipid Bilayer to Anthracycline Derivates. Role of the Bylayer Composition and of the Temperature_. Biochimica et Biophysica Acta. 1389. 13-22. 1998.](https://pubmed.ncbi.nlm.nih.gov/9443599)

#### 25
[E. Galia, E. Nicolaides, D. Härter, R. Läbenberg, C. Reppas, and J. B. Dressman. _Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs_. Pharmaceutical Research. 15. 698-705. 1998.](https://pubmed.ncbi.nlm.nih.gov/9619777)

#### 26
[A. Garg and J. Balthasar. _Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice_. Journal of Pharmacokinetics and Pharmacodynamics. 34. 687-709. 2007.](https://pubmed.ncbi.nlm.nih.gov/17636457)

#### 27
[Henri P. Gavin. _The Levenberg-Marquardt method for nonlinear least squares curve-fitting problems_. 2016.](https://people.duke.edu/%7Ehpgavin/ https://people.duke.edu/~hpgavin/ce281/lm.pdf)

#### 28
[X. Ge, S. Yamamoto, S. Tsutsumi, Y. Midorikawa, S. Ihara, S. M. Wang, and H. Aburatani. _Interpreting expression profiles of cancers by genome- wide survey of breadth of expression in normal tissues_. Genomics.. 86(2). 127-41. 2005.](https://pubmed.ncbi.nlm.nih.gov/15950434/)

#### 29
[R. Gebhardt. _Metabolic zonation of the liver: Regulation and implications for liver function_. Pharmacol. Ther.. 53(3). 275-354. 1992.](https://pubmed.ncbi.nlm.nih.gov/1409850)

#### 30
[J. A. Goldsmith, N. Randall, and S. D. Ross. _On methods of expressing dissolution rate data._. J Pharm Pharmacol. 30(6). 347-9. 1978.](https://pubmed.ncbi.nlm.nih.gov/26763)

#### 31
[H. W. Haagard. _The Absorption, Distribution and Elimination of Ethyl Ether_. The Journal of Biological Chemistry. 59. 753-770. 1924.](https://www.sciencedirect.com/science/article/pii/S0021925818852589)

#### 32
[M. W. Härter, J. Keldenich, and W. Schmitt. in Handbook of Combinatorial Chemistry. Vol. 2. K. C. Nicholaou. R. Hanko. W. Hartwig. Wiley-VCH. Weinheim, Germany. 2002.](https://onlinelibrary.wiley.com/doi/10.1002/3527603034.ch26)

#### 33
[W. L. Hayton. _Maturation and Growth of Renal Function: Dosing Renally Cleared Drugs in Children_. AAPS PharmSci. 2(1). E3. 2002.](https://pubmed.ncbi.nlm.nih.gov/11741219)

#### 34
[P. Holliger and P. J. Hudson. _Engineered antibody fragments and the rise of single domains_. Nat Biotechnol.. 23(9). 1126-36. 2005.](https://pubmed.ncbi.nlm.nih.gov/16151406)

#### 35
[H. G. Holzhutter, D. Drasdo, T. Preusser, J. Lippert, and A. M. Henney. _The virtual liver: a multidisciplinary, multilevel challenge for systems biology_. Wiley Interdiscip Rev Syst Biol Med. 2012.](https://pubmed.ncbi.nlm.nih.gov/22246674)

#### 36
[R. Kawei, M. Lemaire, J. L. Steimer, A. Bruelisauer, W. Niederberger, and M. Rowland. _Physiology Based Pharmacokinetic Study on a Cyclosporin Derivate, SDZ IMM 125_. Journal of Pharmacokinetics and Biopharmaceutics. 22. 327-365. 1994.](https://pubmed.ncbi.nlm.nih.gov/7791036)

#### 37
[G. Kersting, S. Willmann, G. Wurthwein, J. Lippert, J. Boos, and G. Hempel. _Physiologically based pharmacokinetic modelling of high- and low-dose etoposide: from adults to children_. Cancer Chemother Pharmacol. 397-405. 69(2). 2012.](https://pubmed.ncbi.nlm.nih.gov/21789689)

#### 38
[B. Krippendorf, R. Neuhaus, and P. Lienau. _Mechanism-Based Inhibition: Deriving KI and kinact Directly from Time-Dependent IC50 Values_. J. of Biomolecular Screening. 14((8). 2009.](https://pubmed.ncbi.nlm.nih.gov/19675314)

#### 39
[L. Kuepfer, J. Lippert, and T. Eissing. _Multiscale mechanistic modeling in pharmaceutical research and development_. Adv Exp Med Biol. 543-61. 736. 2012.](https://pubmed.ncbi.nlm.nih.gov/22161351)

#### 40
[F. Langenbucher. _Linearization of dissolution rate curves by the Weibull distribution_. J Pharm Pharmacol.. 24(12). 979-81. 1972.](https://pubmed.ncbi.nlm.nih.gov/4146531)

#### 41
[D. G. Levitt. _Physiologically based pharmacokinetic modeling of arterial- antecubital vein concentration difference_. BMC Clinical Pharmacology. 4. 2. 2004.](https://pubmed.ncbi.nlm.nih.gov/15053829)

#### 42
[E. D. Lobo, R. J. Hansen, and J. P. Balthasar. _Antibody Pharmacokinetics and Pharmacodynamics_. J. Pharm. Sci.. 93(11). 2645-2668. 2004.](https://pubmed.ncbi.nlm.nih.gov/15389672)

#### 43
[A. Loidl-Stahlhofen, T. Hartmann, M. Schöttner, C. Röhring, H. Brodowsky, J. Schmitt, and J. Keldenich. _Multilamellar Liposomes and Solid- Supported Lipid Membranes (TRANSIL): Screening of Lipid-Water Partitioning Toward a High-Throughput Scale_. Pharmaceutical Research. 18. 1782-1788. 2001.](https://pubmed.ncbi.nlm.nih.gov/11785701)

#### 44
[G. Loizou, M. Spendiff, H.A. Barton, J. Bessems, F.Y. Bois, M.B. d'Yvoire, H. Buist, H.J. Clewell 3rd, B. Meek, U. Gundert-Remy, G. Goerlitz, and W. Schmitt. _Development of good modelling practice for physiologically based pharmacokinetic models for use in risk assessment: the first steps_. Regulatory Toxicology and Pharmacology. 50(3). 400-11. 2008.](https://pubmed.ncbi.nlm.nih.gov/18331772)

#### 45
[K. Madsen, H.B. Nielsen, and O. Tingleff. _METHODS FOR NON- LINEAR LEAST SQUARES PROBLEMS_. 2nd Edition,  April 2004.](http://www2.imm.dtu.dk/pubdb/views/edoc_download.php/3215/pdf/imm3215.pdf)

#### 46
[M. Meyer, S. Schneckener, B. Ludewig, L. Kuepfer, and J. Lippert. _Using expression data for quantification of active processes in physiologically- based pharmacokinetic modeling_. Drug Metab Dispos. 2012.](https://pubmed.ncbi.nlm.nih.gov/22293118)

#### 47
[John A. Nelder and R. Mead. _A simplex method for function minimization_. Computer Journal. 7. 308-313. 1965.](https://people.duke.edu/~hpgavin/cee201/Nelder+Mead-ComputerJournal-1965.pdf)

#### 48
[I. Nestorov. _Whole-body physiologically based pharmacokinetic models_. Exp Opin Drug Metab Toxicol. 3. 235-249. 2007.](https://pubmed.ncbi.nlm.nih.gov/17428153)

#### 49
[M. Nishimura, H. Yaguti, H. Yoshitsugu, S. Naito, and T. Satoh. _Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR_. Yakugaku Zasshi.. 123(5). 369-75. 2003.](https://pubmed.ncbi.nlm.nih.gov/12772594)

#### 50
[M. Nishimura and S. Naito. _Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies_. Drug Metab Pharmacokinet. 20(6). 452-77. 2005.](https://pubmed.ncbi.nlm.nih.gov/16415531)

#### 51
[M. Nishimura and S. Naito. _Tissue-specific mRNA expression profiles of human phase I metabolizing enzymes except for cytochrome P450 and phase II metabolizing enzymes_. Drug Metab Pharmacokinet. 21(5). 357-74. 2006.](https://pubmed.ncbi.nlm.nih.gov/17072089)

#### 52
[P. Poulin, K. Schoenlein, and F.P. Theil. _Prediction of adipose tissue: plasma partition coefficients for structurally unrelated drugs_. Journal of Pharmaceutical Sciences. 90(4). 436-47. 2001.](https://pubmed.ncbi.nlm.nih.gov/11170034)

#### 53
[P. Poulin and F. P. Theil. _A Priori Prediction of Tissue: Plasma Partition Coefficients of Drugs to Facilitate the Use of Physiologically-Based Pharmacokinetic Models in Drug Discovery_. Journal of Pharmaceutical Sciences. 89. 16-35. 2000.](https://pubmed.ncbi.nlm.nih.gov/10664535)

#### 54
[P. Poulin and F.P. Theil. _Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution_. Journal of Pharmaceutical Sciences. 91(1). 129-56. 2002.](https://pubmed.ncbi.nlm.nih.gov/11782904)

#### 55
[P. Poulin and F.P. Theil. _Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition_. Journal of Pharmaceutical Sciences. 91(5). 1358-70. 2002.](https://pubmed.ncbi.nlm.nih.gov/11977112)

#### 56
[NJ. Proctor, GT. Tucker, and A. Rostami-Hodjegan. _Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors._. Xenobiotica. 34(2). 151-78. 2004.](https://pubmed.ncbi.nlm.nih.gov/14985145)

#### 57
[B. Rippe and B. Haraldsson. _Fluid and protein fluxes across small and large pores in the microvasculature. Application of two-pore equations_. Acta Physiol Scand.. 131(3). pp 411-28. 1987.](https://pubmed.ncbi.nlm.nih.gov/3321914)

#### 58
[B. Rippe and B. Haraldsson. _Transport of macromolecules across microvascular walls: the two-pore theory_. Am Physiological Soc.. 74. pp 163-219. 1994.](https://pubmed.ncbi.nlm.nih.gov/8295933)

#### 59
[T. Rodgers, D. Leahy, and M. Rowland. _Physiologically Based Pharmacokinetic Modeling 1: Predicting the Tissue Distribution of Moderate-to-Strong Bases_. Journal of Pharmaceutical Sciences. 94. 1259-1275. 2005.](https://pubmed.ncbi.nlm.nih.gov/15858854)

#### 60
[T. Rodgers, D. Leahy, and M. Rowland. _Tissue Distribution of Basic Drugs: Accounting for Enantiomeric, Compound and Regional Differences Amongst beta-Blocking Drugs in Rat_. Journal of Pharmaceutical Sciences. 94. 1237-1248. 2005.](https://pubmed.ncbi.nlm.nih.gov/15858851)

#### 61
[T. Rodgers and M. Rowland. _Physiologically Based Pharmacokinetic Modeling 2: Predicting the Tissue Distribution of Acids, Very Weak Bases, Neutrals and Zwitterions_. Journal of Pharmaceutical Sciences. 95. 1238-1257. 2006.](https://pubmed.ncbi.nlm.nih.gov/16639716)

#### 62
[T. Rodgers and M. Rowland. _Mechanistic Approaches to Volume of Distrubtion Predictions: Understanding the Processes_. Pharmaceutical Research. 24. 918-933. 2007.](https://pubmed.ncbi.nlm.nih.gov/17372687)

#### 63
[AD. Rodrigues. _Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes_. Biochem Pharmacol. 465-80. 57 (5). 1999.](https://pubmed.ncbi.nlm.nih.gov/9952310)

#### 64
[A. Rostami-Hodjegan and GT. Tucker. _Simulation and prediction of in vivo drug metabolism in human populations from in vitro data._. Nat Rev Drug Discov. 6(2). 140-8. 2007.](https://pubmed.ncbi.nlm.nih.gov/17268485)

#### 65
M. Rowland and T.N. Tozer. _Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications_. 4th edition. D.B. Troy. Lippincott Williams and Wilkins. Philadelphia, PA 19106. pp. 199. 1984.

#### 66
[T. Sawamato, S. Haruta, Y. Kurosaki, K. Higaki, and T. Kimura. _Prediction of the Plasma Concentration Profiles of Orally Administered Drugs in Rats on the Basis of Gastrointestinal Transit Kinetics and Absorbability_. Journal of Pharmaceutical Pharmacology. 49. 450-457. 1997.](https://pubmed.ncbi.nlm.nih.gov/9232547)

#### 67
[J. Schlender. A report including the description of the physiology base of the Japanese population implemented in PK-Sim®.](https://github.com/Open-Systems-Pharmacology/OSPSuite.Documentation/blob/master/Japanese_Population/Report.md)

#### 68
[W. Schmitt. _General approach for the calculation of tissue to plasma partition coefficients_. Toxicology In Vitro. 22(2). 457-67. 2008.](https://pubmed.ncbi.nlm.nih.gov/17981004)

#### 69
[W. Schmitt and S. Willmann. _Physiology-based pharmacokinetic modeling: ready to be used_. Drug Discov Today. 2. 125-132. 2005.](https://pubmed.ncbi.nlm.nih.gov/24981765)

#### 70
[L. F. Shampine. _Solving ODEs and DDEs with residual control_. Appl. Num. Math.. 52. 113-127. 2005.](https://www.sciencedirect.com/science/article/abs/pii/S0168927404001187)

#### 71
[P. Sidhu, H. T. Peng, B. Cheung, and A. Edginton. _Simulation of differential drug pharmacokinetics under heat and exercise stress using a physiologically based pharmacokinetic modeling approach_. Can J Physiol Pharmacol. 365-82. 89(5). 2011.](https://pubmed.ncbi.nlm.nih.gov/21627485)

#### 72
[R.B. Silvermann. _Mechanism-based enzyme inhibitors_. Methods in Enzymology. 249. 1995.](https://pubmed.ncbi.nlm.nih.gov/7791614)

#### 73
[A. Strougo, T. Eissing, A. Yassen, S. Willmann, M. Danhof, and J. Freijer. _First dose in children: physiological insights into pharmacokinetic scaling approaches and their implications in paediatric drug development_. J Pharmacokinet Pharmacodyn. 2012.](https://pubmed.ncbi.nlm.nih.gov/22311388)

#### 74
G. Tanaka and H. Kawamura. _Anatomical and physiological characteristics for Asian reference man: Male and female of different ages: Tanaka model_. Division of Radioecology. National Institute of Radiological Sciences. Hitachinaka 311-12 Japan. Report Number NIRS-M-115. 1996.

#### 75
[A. Terenji, S. Willmann, J. Osterholz, P. Hering, and H. J. Schwarzmaier. _Measurement of the coagulation dynamics of bovine liver using the modified microscopic Beer-Lambert law_. Lasers Surg Med. 365-70. 36(5). 2005.](https://pubmed.ncbi.nlm.nih.gov/15825206)

#### 76
[F. P. Theil, T. W. Guentert, S. Haddad, and P. Poulin. _Utility of Physiologically Based Pharmacokinetic Models to Drug Development and Rational Drug Discovery Candidate Selection_. Toxicology Letters. 138. 29-49. 2003.](https://pubmed.ncbi.nlm.nih.gov/12559691)

#### 77  
[K. Thelen and J.B. Dressman. _Cytochrome P450-mediated metabolism in the human gut wall_. Journal of Pharmacokinetics and Pharmacodynamics. 61(5). 541-58. 2009.](https://pubmed.ncbi.nlm.nih.gov/19405992)

#### 78
[K. Thelen, E. Jantratid, J. B. Dressman, J. Lippert, and S. Willmann. _Analysis of nifedipine absorption from soft gelatin capsules using PBPK modeling and biorelevant dissolution testing_. J Pharm Sci. 2899-904. 99(6). 2010.](https://pubmed.ncbi.nlm.nih.gov/20014280)

#### 79
[K. Thelen, K. Coboeken, S. Willmann, R. Burghaus, J. B. Dressman, and J. Lippert. _Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part 1: oral solutions_. J Pharm Sci. 5324-45. 100(12). 2011.](https://pubmed.ncbi.nlm.nih.gov/21993815)

#### 80
[K. Thelen, K. Coboeken, S. Willmann, J. B. Dressman, and J. Lippert. _Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part II: extension to describe performance of solid dosage forms_. J Pharm Sci. 1267-80. 101(3). 2012.](https://pubmed.ncbi.nlm.nih.gov/22125236)

#### 81
[K. Thelen, K. Coboeken, Y. Jia, J.B. Dressman, S. Willmann. _Dynamically simulating the effect of food on gastric emptying using a detailed physiological model for gastrointestinal transit and absorption_. PAGE meeting 2012. Venice, Italy. 2012.](https://www.page-meeting.org/default.asp?abstract=2355)

#### 82
[Third National Health and Nutrition Examination Survey, (NHANES III). 1997\. National Center for Health Statistics Hyattsville, MD 20782](http://www.cdc.gov/nchs/nhanes.htm)

#### 83
[Expressed Sequence Tags (EST) from UniGene. 2010\. National Center for Biotechnology Information (NCBI)](https://ftp.ncbi.nlm.nih.gov/repository/UniGene/)

#### 84
[Annals of the ICRP. Basic Anatomical and Physiological Data for Use in Radiological Protection: Reference Values. J. Valentin. Vol. 32 (3-4). 2002.](https://pubmed.ncbi.nlm.nih.gov/14506981)

#### 85
[P. H. van der Graaf and N. Benson. _Systems pharmacology: bridging systems biology and pharmacokineticspharmacodynamics (PKPD) in drug discovery and development_. Pharm Res. 1460-4. 28(7). 2011.](https://pubmed.ncbi.nlm.nih.gov/21560018)

#### 86
[B. van Ommen, J. de Jongh, J. van de Sandt, B. Blaauboer, E. Hissink, J. Bogaards, and P. Bladeren. _Computer-aided Biokinetic Modelling Combined with In Vitro Data_. Toxicology In Vitro. 9. 537-542. 1995.](https://pubmed.ncbi.nlm.nih.gov/20650125)

#### 87
[M. Vossen, M. Sevestre, C. Niederalt, I. J. Jang, S. Willmann, and A. N. Edginton. _Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models_. Theor Biol Med Model. 13. 4. 2007.](https://pubmed.ncbi.nlm.nih.gov/17386084)

#### 88
[W. Wang, E. Q. Wang, and J.P. Balthasar. _Monoclonal Antibody Pharmacokinetics and Pharmacodynamics_. Clin Pharmacol Ther.. 548-58. 84(5). 2008.](https://pubmed.ncbi.nlm.nih.gov/18784655)

#### 89
[O. Weber, S. Willmann, H. Bischoff, V. Li, A. Vakalopoulos, K. Lustig, F. T. Hafner, R. Heinig, C. Schmeck, and K. Buehner. _Prediction of a potentially effective dose in humans for BAY 60-5521, a potent inhibitor of cholesteryl ester transfer protein (CETP) by allometric species scaling and combined pharmacodynamic and physiologically-based pharmacokinetic modelling_. Br J Clin Pharmacol. 219-31. 73(2). 2012.](https://pubmed.ncbi.nlm.nih.gov/21762205)

#### 90
[S. Willmann, H. J. Schwarzmaier, A. Terenji, I. V. Yaroslavsky, and P. Hering. _Quantitative microspectrophotometry in turbid media_. Appl Opt. 4904-13. 38(22). 1999.](https://pubmed.ncbi.nlm.nih.gov/18323981)

#### 91
[S. Willmann, A. Terenji, H. Busse, I. V. Yaroslavsky, A. N. Yaroslavsky, H. J. Schwarzmaier, and P. Hering. _Scattering delay time of Mie scatterers determined from steady-state and time-resolved optical spectroscopy_. J Opt Soc Am A Opt Image Sci Vis. 745-9. 17(4). 2000.](https://pubmed.ncbi.nlm.nih.gov/10757182)

#### 92
[S. Willmann, J. Lippert, M. Sevestre, J. Solodenko, F. Fois, and W. Schmitt. PK-Sim®: A physiologically based pharmacokinetic 'whole-body' model. Biosilico. 1. 121-124. 2003.](https://www.sciencedirect.com/science/article/abs/pii/S1478538203023424)

#### 93
[S. Willmann, W. Schmitt, J. Keldenich, and J. B. Dressman. _A Physiologic Model for Simulating Gastrointestinal Flow and Drug Absorption in Rats_. Pharmaceutical Research. 20. 1766-1771. 2003.](https://pubmed.ncbi.nlm.nih.gov/14661920)

#### 94
[S. Willmann, A. Terenji, J. Osterholz, J. Meister, P. Hering, and H.J. Schwarzmaier. _Small-volume frequency-domain oximetry: phantom experiments and first in vivo results_. J Biomed Opt. 618-28. 8(4). 2003.](https://pubmed.ncbi.nlm.nih.gov/14563199)

#### 95
[S. Willmann, W. Schmitt, J. Keldenich, J. Lippert, and J. B. Dressman. _A Physiological Model for the Estimation of Fraction Dose Absorbed in Humans_. Journal of Medical Chemistry. 47. 4022-4031. 2004.](https://pubmed.ncbi.nlm.nih.gov/15267240)

#### 96
[S. Willmann, J. Lippert, and W. Schmitt. _From physicochemistry to absorption and distribution: predictive mechanistic modelling and computational tools_. Expert Opinion on Drug Metabolism and Toxicology. 1. 159-168. 2005.](https://pubmed.ncbi.nlm.nih.gov/16922658)

#### 97
[S. Willmann, K. Hoehn, A. N. Edginton, M. Sevestre, J. Solodenko, W. Weiss, J. Lippert, and W. Schmitt. _Development of a physiologically-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs_. Journal of Pharmacokinetics and Pharmacodynamics. 34(3). 401-431. 2007.](https://pubmed.ncbi.nlm.nih.gov/17431751)

#### 98
[S. Willmann, A.N. Edginton, and J.B. Dressman. _Development and validation of a physiology-based model for the prediction of oral absorption in monkeys_. Pharmaceutical Research. 24(7). 1275-82. 2007.](https://pubmed.ncbi.nlm.nih.gov/17373575)

#### 99
[S. Willmann, A.N. Edginton, M. Kleine-Besten, E. Jantratid, K. Thelen, and J.B. Dressman. _Whole-Body Physiologically-Based Pharmacokinetic Population Modelling of Oral Drug Administration: Inter-Individual Variability of Cimetidine Absorption_. Journal of Pharmacokinetics and Pharmacodynamics. 61. 891-9. 2009.](https://pubmed.ncbi.nlm.nih.gov/19589231)

#### 100
[S. Willmann, A.N. Edginton, K. Coboeken, G. Ahr, and J. Lippert. _Risk to the Breast-Fed Neonate From Codeine Treatment to the Mother: A Quantitative Mechanistic Modeling Study_. Clinical Pharmacology and Therapeutics. advance online publication. 2009.](https://pubmed.ncbi.nlm.nih.gov/19710640)

#### 101
[S. Willmann. _The in silico Child. Can computer simulations replace clinical pharmacokinetic studies?_. Original: Das In-silico-Child. Konnen Computer-Simulationen klinisch-pharmakokinetische Studien ersetzen?. Pharm Unserer Zeit. 62-7. 38(1). 2009.](https://pubmed.ncbi.nlm.nih.gov/19132649)

#### 102
[S. Willmann, K. Thelen, C. Becker, J. B. Dressman, and J. Lippert. _Mechanism-based prediction of particle size-dependent dissolution and absorption: cilostazol pharmacokinetics in dogs_. Eur J Pharm Biopharm. 83-94. 76(1). 2010.](https://pubmed.ncbi.nlm.nih.gov/20554023)

#### 103
Y. Wu and F. Kesisoglou. _Immediate Release Oral Dosage Forms: Formulation Screening in the Pharmaceutical Industry_. in: Oral Drug Absorption: Prediction and Assessment. J. J. Dressman. C. Reppas. Informa Healthcare. New York, USA. pp. 323. 2009.

#### 104
[J. Yang, M. Jamei, and K. Rowland Yeo. _Theoretical assessment of a new experimental protocol for determining kinetic values describing mechanism (time)-based enzyme inhibition_ . European Journal in Pharmaceutical Sciences. 31. 2007.](https://pubmed.ncbi.nlm.nih.gov/17512176)

#### 105
[H. Zischka, C. J. Gloeckner, C. Klein, S. Willmann, M. Swiatek-de Lange, and M. Ueffing. _Improved mass spectrometric identification of gel- separated hydrophobic membrane proteins after sodium dodecyl sulfate removal by ion-pair extraction_. Proteomics. 3776-82. 4(12). 2004.](https://pubmed.ncbi.nlm.nih.gov/15540170)

#### 106
[Hanke N, Frechen S, Moj D, Britz H, Eissing T, Wendl T, Lehr T. *PBPK models for  CYP3A4 and P‐gp DDI prediction: a modeling network of rifampicin,  itraconazole, clarithromycin, midazolam, alfentanil and digoxin.*](https://www.ncbi.nlm.nih.gov/pubmed/30091221)

#### 107
[Dallmann A, Ince I, Solodenko J, et al. Physiologically Based Pharmacokinetic Modeling of Renally Cleared Drugs in Pregnant Women. Clin Pharmacokinet. 2017;56(12):1525-1541. doi:10.1007/s40262-017-0538-0](https://pubmed.ncbi.nlm.nih.gov/28391404)

#### 108
[Dallmann A, Ince I, Meyer M, Willmann S, Eissing T, Hempel G. Gestation-Specific Changes in the Anatomy and Physiology of Healthy Pregnant Women: An Extended Repository of Model Parameters for Physiologically Based Pharmacokinetic Modeling in Pregnancy. Clin Pharmacokinet. 2017;56(11):1303-1330. doi:10.1007/s40262-017-0539-z](https://pubmed.ncbi.nlm.nih.gov/28401479)

#### 109
[Dallmann A, Ince I, Coboeken K, Eissing T, Hempel G. A Physiologically Based Pharmacokinetic Model for Pregnant Women to Predict the Pharmacokinetics of Drugs Metabolized Via Several Enzymatic Pathways. Clin Pharmacokinet. 2018;57(6):749-768. doi:10.1007/s40262-017-0594-5](https://pubmed.ncbi.nlm.nih.gov/28924743)

#### 110
[Dallmann A, Solodenko J, Ince I, Eissing T. Applied Concepts in PBPK Modeling: How to Extend an Open Systems Pharmacology Model to the Special Population of Pregnant Women. CPT Pharmacometrics Syst Pharmacol. 2018;7(7):419-431. doi:10.1002/psp4.12300](https://pubmed.ncbi.nlm.nih.gov/29569837)

#### 111
[Claassen K, Thelen K, Coboeken K, et al.  Development of a Physiologically-Based Pharmacokinetic Model for Preterm Neonates: Evaluation with In Vivo Data. *Curr Pharm Des*. 2015;21(39):5688-5698. doi:10.2174/1381612821666150901110533](https://pubmed.ncbi.nlm.nih.gov/26323410)

#### 112
[Mavroudis PD, Hermes HE, Teutonico D, Preuss TG, Schneckener S. Development and validation of a physiology-based model for the prediction of pharmacokinetics/toxicokinetics in rabbits. *PLoS One*. 2018;13(3):e0194294. Published 2018 Mar 21. doi:10.1371/journal.pone.0194294](https://pubmed.ncbi.nlm.nih.gov/29561908)

#### 113
[Schlender JF, Meyer M, Thelen K, et al. Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals.
*Clin Pharmacokinet*. 2016;55(12):1573-1589. doi:10.1007/s40262-016-0422-3](https://pubmed.ncbi.nlm.nih.gov/27351180/)

#### 114
[Niederalt C, Kuepfer L, Solodenko J, et al. A generic whole body physiologically based pharmacokinetic model for therapeutic proteins in PK-Sim. *J Pharmacokinet Pharmacodyn*. 2018;45(2):235-257. doi:10.1007/s10928-017-9559-4](https://pubmed.ncbi.nlm.nih.gov/29234936)

#### 115
[Lippert J, Burghaus R, Edginton A, et al.  Open Systems Pharmacology Community-An Open Access, Open Source, Open Science Approach to Modeling and Simulation in Pharmaceutical Sciences. *CPT Pharmacometrics Syst Pharmacol*. 2019;8(12):878-882. doi:10.1002/psp4.12473](https://pubmed.ncbi.nlm.nih.gov/31671256)

#### 116
[Kuepfer L, Niederalt C, Wendl T, et al. Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model. *CPT Pharmacometrics Syst Pharmacol*. 2016;5(10):516-531. doi:10.1002/psp4.12134](https://pubmed.ncbi.nlm.nih.gov/27653238)

#### 117
[EFPIA MID3 Workgroup, Marshall SF, Burghaus R, et al. Good Practices in Model-Informed Drug Discovery and Development: Practice, Application, and Documentation. *CPT Pharmacometrics Syst Pharmacol*. 2016;5(3):93-122. doi:10.1002/psp4.12049](https://pubmed.ncbi.nlm.nih.gov/27069774)

#### 118
[Schneckener S, Preuss TG, Kuepfer L, Witt J. A workflow to build PBTK models for novel species. *Arch Toxicol*. 2020;94(11):3847-3860. doi:10.1007/s00204-020-02922-z](https://pubmed.ncbi.nlm.nih.gov/33033842)

#### 119
[Ince I, Solodenko J, Frechen S, et al. Predictive Pediatric Modeling and Simulation Using Ontogeny Information. *J Clin Pharmacol*. 2019;59 Suppl 1:S95-S103. doi:10.1002/jcph.1497](https://pubmed.ncbi.nlm.nih.gov/31502689)

#### 120
[Sjögren E, Tarning J, Barnes KI, Jonsson EN. A Physiologically-Based Pharmacokinetic Framework for Prediction of Drug  Exposure in Malnourished Children. *Pharmaceutics*. 2021;13(2):204. Published 2021 Feb 2. doi:10.3390/pharmaceutics13020204](https://pubmed.ncbi.nlm.nih.gov/33540928)

#### 121
[Frechen S, Solodenko J, Wendl T, et al. A generic framework for the physiologically-based pharmacokinetic platform qualification of PK-Sim and its application to predicting cytochrome P450 3A4-mediated drug-drug interactions. CPT Pharmacometrics Syst Pharmacol. 2021;10(6):633-644. doi:10.1002/psp4.12636](https://pubmed.ncbi.nlm.nih.gov/33946131)

#### 122
[Paul R.V. Malik, Cindy H.T. Yeung, Shams Ismaeil, Urooj Advani, Sebastian Djie, Andrea N. Edginton. A Physiological Approach to Pharmacokinetics in Chronic Kidney Disease](https://accp1.onlinelibrary.wiley.com/doi/full/10.1002/jcph.1713)

#### 123 
[FDA Meeting: Development of Best Practices in Physiologically Based Pharmacokinetic Modeling to Support Clinical Pharmacology Regulatory Decision-Making](https://www.fda.gov/drugs/news-events-human-drugs/development-best-practices-physiologically-based-pharmacokinetic-modeling-support-clinical)

#### 124
[Peters and Dolgos. Requirements to Establishing Confidence in Physiologically Based Pharmacokinetic (PBPK) Models and Overcoming Some of the Challenges to Meeting Them.](https://doi.org/10.1007/s40262-019-00790-0)

#### 125
[FDA, Center for Drug Evaluation and. 2019. “Physiologically Based Pharmacokinetic Analyses — Format and Content Guidance for Industry.” U.S. Food and Drug Administration. October 18, 2019.](http://www.fda.gov/regulatory-information/search-fda-guidance-documents/physiologically-based-pharmacokinetic-analyses-format-and-content-guidance-industry)

#### 126
[EMA Guideline: Guideline on the qualification and reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation.](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-qualification-reporting-physiologically-based-pharmacokinetic-pbpk-modelling-simulation_en.pdf)

#### 127
[EMA Guideline: Guideline on the use of physiologically based pharmacokinetic (PBPK) modelling in the assessment of regulatory pharmacokinetic applications.](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-use-physiologically-based-pharmacokinetic-pbpk-modelling-assessment-regulatory-pharmacokinetic_en.pdf)

#### 128
[Shebley et al. Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective.](https://doi.org/10.1002/cpt.1013 )

#### 129
[Miller et al. Physiologically Based Pharmacokinetic Modelling for First‐In‐Human Predictions: An Updated Model Building Strategy Illustrated with Challenging Industry Case Studies.](https://doi.org/10.1007/s40262-019-00741-9) 

#### 130
[OECD (2021), Guidance document on the characterisation, validation and reporting of Physiologically Based Kinetic (PBK) models for regulatory purposes, OECD Series on Testing and Assessment, No. 331, OECD Publishing, Paris](https://www.oecd.org/content/dam/oecd/en/publications/reports/2021/02/guidance-document-on-the-characterisation-validation-and-reporting-of-physiologically-based-kinetic-pbk-models-for-regulatory-purposes_670da2f4/d0de241f-en.pdf)

#### 131
[Calvier, Elisa A. M., Thu Thuy Nguyen, Trevor N. Johnson, Amin Rostami-Hodjegan, Dick Tibboel, Elke H. J. Krekels, and Catherijne A. J. Knibbe. 2018. “Can Population Modelling Principles Be Used to Identify Key PBPK Parameters for Paediatric Clearance Predictions? An Innovative Application of Optimal Design Theory.” *Pharmaceutical Research* 35 (11): 209.](https://doi.org/10.1007/s11095-018-2487-1)

#### 132
[Dallmann, André, Ibrahim Ince, Juri Solodenko, Michaela Meyer, Stefan Willmann, Thomas Eissing, and Georg Hempel. 2017. “Physiologically Based Pharmacokinetic Modeling of Renally Cleared Drugs in Pregnant Women.” Clinical Pharmacokinetics 56 (12): 1525–41.](https://doi.org/10.1007/s40262-017-0538-0)

#### 133
[Doki, Kosuke, Adam S. Darwich, Nikunjkumar Patel, and Amin Rostami-Hodjegan. 2017. “Virtual Bioequivalence for Achlorhydric Subjects: The Use of PBPK Modelling to Assess the Formulation-Dependent Effect of Achlorhydria.” European Journal of Pharmaceutical Sciences 109 (November): 111–20.](https://doi.org/10.1016/j.ejps.2017.07.035)

#### 134
[Fendt, Rebekka, Hofmann, Ute, Schneider, Annika R.P., Schaeffeler, Elke, Burghaus, Rolf, et al. 2021. “Data-Driven Personalization of a Physiologically Based Pharmacokinetic Model for Caffeine: A Systematic Assessment” CPT: Pharmacometrics & Systems Pharmacology.](https://doi.org/10.1002/psp4.12646)

#### 135
[Grimstein, Manuela, Yuching Yang, Xinyuan Zhang, Joseph Grillo, Shiew-Mei Huang, Issam Zineh, and Yaning Wang. 2019. “Physiologically Based Pharmacokinetic Modeling in Regulatory Science: An Update From the U.S. Food and Drug Administration’s Office of Clinical Pharmacology.” Journal of Pharmaceutical Sciences 108 (1): 21–25.](https://doi.org/10.1016/j.xphs.2018.10.033)

#### 136
[Heimbach, Tycho, Yuan Chen, Jun Chen, Vaishali Dixit, Neil Parrott, Sheila Annie Peters, Italo Poggesi, et al. 2020. “Physiologically-Based Pharmacokinetic Modeling in Renal and Hepatic Impairment Populations: A Pharmaceutical Industry Perspective.” Clinical Pharmacology & Therapeutics n/a (n/a).](https://doi.org/10.1002/cpt.2125)

#### 137
[Kuemmel, Colleen, Yan, Yuching, Zhang, Xiyuan, Florian, Jeffry, Zhu, Hao et al. 2019.” Consideration of a Credibility Assessment Framework in Model-Informed Drug Development: Potential Application to PBPK Modeling and Simulation” CPT: Pharmacometrics & Systems Pharmacology.](https://doi.org/10.1002/psp4.12479)

#### 138
[Lin, Wen, Jing-He Yan, Tycho Heimbach, and Handan He. 2018. “Pediatric Physiologically Based Pharmacokinetic Model Development: Current Status and Challenges.” Current Pharmacology Reports 4 (6): 491–501.](https://doi.org/10.1007/s40495-018-0162-1)

#### 139
[Loisios-Konstantinidis, Ioannis, Rodrigo Cristofoletti, Nikoletta Fotaki, David B. Turner, and Jennifer Dressman. 2020. “Establishing Virtual Bioequivalence and Clinically Relevant Specifications Using in Vitro Biorelevant Dissolution Testing and Physiologically-Based Population Pharmacokinetic Modeling. Case Example: Naproxen.” European Journal of Pharmaceutical Sciences 143 (February): 105170.](https://doi.org/10.1016/j.ejps.2019.105170)

#### 140
[Loisios-Konstantinidis, Ioannis, Bart Hens, Amitava Mitra, Sarah Kim, Chang Chiann, and Rodrigo Cristofoletti. 2020. “Using Physiologically Based Pharmacokinetic Modeling to Assess the Risks of Failing Bioequivalence Criteria: A Tale of Two Ibuprofen Products.” The AAPS Journal 22 (5): 113.](https://doi.org/10.1208/s12248-020-00495-4)

#### 141
[Morcos, Peter N., Yumi Cleary, Carolina Sturm‐Pellanda, Elena Guerini, Markus Abt, Massimiliano Donzelli, Faye Vazvaei, Bogdana Balas, Neil Parrott, and Li Yu. 2018. “Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib.” The Journal of Clinical Pharmacology 58 (12): 1618–28.](https://doi.org/10.1002/jcph.1286)

#### 142
[Peters, Sheila Annie, and Hugues Dolgos. 2019. “Requirements to Establishing Confidence in Physiologically Based Pharmacokinetic (PBPK) Models and Overcoming Some of the Challenges to Meeting Them.” Clinical Pharmacokinetics 58 (11): 1355–71.](https://doi.org/10.1007/s40262-019-00790-0)

#### 143
[Rimmler, Christer, Christian Lanckohr, Ceren Akamp, Dagmar Horn, Manfred Fobker, Karsten Wiebe, Bassam Redwan, Bjoern Ellger, Robin Koeck, and Georg Hempel. 2019. “Physiologically Based Pharmacokinetic Evaluation of Cefuroxime in Perioperative Antibiotic Prophylaxis.” British Journal of Clinical Pharmacology 85 (12): 2864–77.](https://doi.org/10.1111/bcp.14121)

#### 144
[Tan, Ming-Liang, Ping Zhao, Lei Zhang, Yunn-Fang Ho, Manthena V. S. Varma, Sibylle Neuhoff, Thomas D. Nolin, Aleksandra Galetin, and Shiew-Mei Huang. 2019. “Use of Physiologically Based Pharmacokinetic Modeling to Evaluate the Effect of Chronic Kidney Disease on the Disposition of Hepatic CYP2C8 and OATP1B Drug Substrates.” Clinical Pharmacology & Therapeutics 105 (3): 719–29.](https://doi.org/10.1002/cpt.1205)

#### 145
[Türk, Denise, Nina Hanke, and Thorsten Lehr. 2020. “A Physiologically-Based Pharmacokinetic Model of Trimethoprim for MATE1, OCT1, OCT2, and CYP2C8 Drug–Drug–Gene Interaction Predictions.” Pharmaceutics 12 (11): 1074.](https://doi.org/10.3390/pharmaceutics12111074)

#### 146
[Wagner, C., P. Zhao, Y. Pan, V. Hsu, J. Grillo, S. M. Huang, and V. Sinha. 2015. “Application of Physiologically Based Pharmacokinetic (PBPK) Modeling to Support Dose Selection: Report of an FDA Public Workshop on PBPK.” CPT: Pharmacometrics & Systems Pharmacology 4 (4): 226–30.](https://doi.org/10.1002/psp4.33)

#### 147
[Yun, Yejin Esther, and Andrea N. Edginton. 2019. “Model Qualification of the PK-Sim® Pediatric Module for Pediatric Exposure Assessment of CYP450 Metabolized Compounds.” Journal of Toxicology and Environmental Health. Part A 82 (14): 789–814.](https://doi.org/10.1080/15287394.2019.1652215)

#### 148
[Zhao, P, L Zhang, J A Grillo, Q Liu, J M Bullock, Y J Moon, P Song, et al. 2011. “Applications of Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation During Regulatory Review.” Clinical Pharmacology & Therapeutics 89 (2): 259–67.](https://doi.org/10.1038/clpt.2010.298)

#### 149
[Zhou, Diansong, Terry Podoll, Yan Xu, Ganesh Moorthy, Karthick Vishwanathan, Joseph Ware, J. Greg Slatter, and Nidal Al‐Huniti. 2019. “Evaluation of the Drug–Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP-5862, Using a Physiologically-Based Pharmacokinetic Modeling Approach.” CPT: Pharmacometrics & Systems Pharmacology 8 (7): 489–99.](https://doi.org/10.1002/psp4.12408)

#### 150
[Zhuang, Xiaomei, and Chuang Lu. 2016. “PBPK Modeling and Simulation in Drug Research and Development.” Acta Pharmaceutica Sinica. B 6 (5): 430–40.](https://doi.org/10.1016/j.apsb.2016.04.004)

#### 151

Kuemmel, C., Yang, Y., Zhang, X., Florian, J., Zhu, H., Tegenge, M., Huang, S.-M., Wang, Y., Morrison, T., & Zineh, I. (2020). Consideration of a Credibility Assessment Framework in Model-Informed Drug Development: Potential Application to Physiologically-Based Pharmacokinetic Modeling and Simulation. CPT: Pharmacometrics & Systems Pharmacology, 9(1), 21–28

#### 152
[Rüdesheim, S., Wojtyniak, J.-G., Selzer, D., Hanke, N., Mahfoud, F., Schwab, M., & Lehr, T. (2020). Physiologically Based Pharmacokinetic Modeling of Metoprolol Enantiomers and α-Hydroxymetoprolol to Describe CYP2D6 Drug-Gene Interactions. Pharmaceutics, 12(12).](https://doi.org/10.3390/pharmaceutics12121200)

#### 153
Utsey, K., Gastonguay, M. S., Russell, S., Freling, R., Riggs, M. M., & Elmokadem, A. (2020). Quantification of the Impact of Partition Coefficient Prediction Methods on Physiologically Based Pharmacokinetic Model Output Using a Standardized Tissue Composition. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 48(10), 903–916.

#### 154
[Peters and Dolgos. Requirements to Establishing Confidence in Physiologically Based Pharmacokinetic (PBPK) Models and Overcoming Some of the Challenges to Meeting Them.](https://doi.org/10.1007/s40262-019-00790-0)

#### 155
McNally, K., Cotton, R., & Loizou, G. D. (2011). A Workflow for Global Sensitivity Analysis of PBPK Models. Frontiers in Pharmacology, 2, 31.

#### 156
Peters, S. A. (Ed.). (2012). Variability, Uncertainty, and Sensitivity Analysis. In Physiologically-Based Pharmacokinetic (PBPK) Modeling and Simulations (Vol. 120, pp. 161–181). John Wiley & Sons, Inc.

#### 157
Hsieh, N.-H., Reisfeld, B., Bois, F. Y., & Chiu, W. A. (2018). Applying a Global Sensitivity Analysis Workflow to Improve the Computational Efficiencies in Physiologically-Based Pharmacokinetic Modeling. Frontiers in Pharmacology, 9, 588.

#### 158
Zhang, X.-Y., Trame, M. N., Lesko, L. J., & Schmidt, S. (2015). Sobol Sensitivity Analysis: A Tool to Guide the Development and Evaluation of Systems Pharmacology Models. CPT: Pharmacometrics & Systems Pharmacology, 4(2), 69–79.

#### 159
[Miller, Neil A., Micaela B. Reddy, Aki T. Heikkinen, Viera Lukacova, and Neil Parrott. 2019. “Physiologically Based Pharmacokinetic Modelling for First-In-Human Predictions: An Updated Model Building Strategy Illustrated with Challenging Industry Case Studies.” Clinical Pharmacokinetics, February. ](https://doi.org/10.1007/s40262-019-00741-9)

#### 160
[Cho, Hyun-Jong, Ji-Eon Kim, Dae-Duk Kim, and In-Soo Yoon. 2014. “In Vitro-in Vivo Extrapolation (IVIVE) for Predicting Human Intestinal Absorption and First-Pass Elimination of Drugs: Principles and Applications.” Drug Development and Industrial Pharmacy 40 (8): 989–98.](https://doi.org/10.3109/03639045.2013.831439)

#### 161
[Poulin, Patrick, Hannah M. Jones, Rhys Do Jones, James W.T. Yates, Christopher R. Gibson, Jenny Y. Chien, Barbara J. Ring, et al. 2011. “PhRMA CPCDC Initiative on Predictive Models of Human Pharmacokinetics, Part 1: Goals, Properties of the Phrma Dataset, and Comparison with Literature Datasets.” Journal of Pharmaceutical Sciences 100 (10): 4050–73.](https://doi.org/10.1002/jps.22554)

#### 162
[Berezhkovskiy, Leonid M. 2004. “Volume of Distribution at Steady State for a Linear Pharmacokinetic System with Peripheral Elimination.” Journal of Pharmaceutical Sciences 93 (6): 1628–40.](https://doi.org/10.1002/jps.20073)

#### 163
[Poulin, P., and F. P. Theil. 2000. “A Priori Prediction of Tissue:Plasma Partition Coefficients of Drugs to Facilitate the Use of Physiologically-Based Pharmacokinetic Models in Drug Discovery.” Journal of Pharmaceutical Sciences 89 (1): 16–35.](https://doi.org/10.1002/(SICI)1520-6017(200001)89:1<16::AID-JPS3>3.0.CO;2-E) **TODO Link not working**

#### 164
[Rodgers, Trudy, David Leahy, and Malcolm Rowland. 2005. “Physiologically Based Pharmacokinetic Modeling 1: Predicting the Tissue Distribution of Moderate-to-Strong Bases.” Journal of Pharmaceutical Sciences 94 (6): 1259–76.](https://doi.org/10.1002/jps.20322)

#### 165
[Benet, Leslie Z., and Jasleen K. Sodhi. 2020. “Investigating the Theoretical Basis for In Vitro–In Vivo Extrapolation (IVIVE) in Predicting Drug Metabolic Clearance and Proposing Future Experimental Pathways.” The AAPS Journal 22 (5): 120.](https://doi.org/10.1208/s12248-020-00501-9)

#### 166
[Kumar, Vineet, Jia Yin, Sarah Billington, Bhagwat Prasad, Colin D. A. Brown, Joanne Wang, and Jashvant D. Unadkat. 2018. “The Importance of Incorporating OCT2 Plasma Membrane Expression and Membrane Potential in IVIVE of Metformin Renal Secretory Clearance.” Drug Metabolism and Disposition: The Biological Fate of Chemicals 46 (10): 1441–45.](https://doi.org/10.1124/dmd.118.082313)

#### 167
[Trapa, Patrick E., Matthew D. Troutman, Thomas Y. Lau, Travis T. Wager, Tristan S. Maurer, Nandini C. Patel, Mark A. West, et al. 2019. “In Vitro–In Vivo Extrapolation of Key Transporter Activity at the Blood–Brain Barrier.” Drug Metabolism and Disposition 47 (4): 405–11.](https://doi.org/10.1124/dmd.118.083279)

#### 168
[Kuepfer, L, C Niederalt, T Wendl, J-F Schlender, S Willmann, J Lippert, M Block, T Eissing, and D Teutonico. 2016. “Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model: Applied Concepts in PBPK Modeling.” CPT: Pharmacometrics & Systems Pharmacology 5 (10): 516–31.](https://doi.org/10.1002/psp4.12134)

#### 169
[Marshall, S. F., R. Burghaus, V. Cosson, S. Y. A. Cheung, M. Chenel, O. DellaPasqua, N. Frey, et al. 2016. “Good Practices in Model-Informed Drug Discovery and Development: Practice, Application, and Documentation.” CPT: Pharmacometrics & Systems Pharmacology 5 (3): 93–122.](https://doi.org/10.1002/psp4.12049)

#### 170
[Tan, Yu-Mei, Melissa Chan, Amechi Chukwudebe, Jeanne Domoradzki, Jeffrey Fisher, C. Eric Hack, Paul Hinderliter, et al. 2020. “PBPK Model Reporting Template for Chemical Risk Assessment Applications.” Regulatory Toxicology and Pharmacology 115 (August): 104691.](https://doi.org/10.1016/j.yrtph.2020.104691)